These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 25038532)

  • 21. A different interpretation of the efficacy of lung cancer screening in the PLCO trial.
    Sagawa M; Nakayama T; Sobue T;
    Eur J Epidemiol; 2016 Feb; 31(2):211-2. PubMed ID: 26197850
    [No Abstract]   [Full Text] [Related]  

  • 22. Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: the first six years.
    Simpson NK; Johnson CC; Ogden SL; Gamito E; Trocky N; McGuire C; Martin J; Barrow S; Lamerato L; Flickinger LM; Broski KG; Engelhard D; Hilke C; Bonk J; Gahagan B; Gren LH; Childs J; Lappe K; Fouad M; Thompson J; Sullivan D;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):356S-378S. PubMed ID: 11189688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomization to screening for prostate, lung, colorectal and ovarian cancers and thyroid cancer incidence in two large cancer screening trials.
    O'Grady TJ; Kitahara CM; DiRienzo AG; Boscoe FP; Gates MA
    PLoS One; 2014; 9(9):e106880. PubMed ID: 25192282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination.
    Weissfeld JL; Schoen RE; Pinsky PF; Bresalier RS; Doria-Rose VP; Laiyemo AO; Church T; Yokochi LA; Yurgalevitch S; Rathmell J; Andriole GL; Buys S; Crawford ED; Fouad M; Isaacs C; Lamerato L; Reding D; Prorok PC; Berg CD;
    J Natl Cancer Inst; 2012 Feb; 104(4):280-9. PubMed ID: 22298838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective investigation of body mass index, colorectal adenoma, and colorectal cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Kitahara CM; Berndt SI; de González AB; Coleman HG; Schoen RE; Hayes RB; Huang WY
    J Clin Oncol; 2013 Jul; 31(19):2450-9. PubMed ID: 23715565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Black A; Parnes HL; Grubb R; David Crawford E; Miller A; Reding D; Andriole G
    Cancer Epidemiol; 2012 Dec; 36(6):e401-6. PubMed ID: 23000116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities.
    Laiyemo AO; Doubeni C; Pinsky PF; Doria-Rose VP; Bresalier R; Lamerato LE; Crawford ED; Kvale P; Fouad M; Hickey T; Riley T; Weissfeld J; Schoen RE; Marcus PM; Prorok PC; Berg CD
    J Natl Cancer Inst; 2010 Apr; 102(8):538-46. PubMed ID: 20357245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Managing Multi-Center Recruitment in the PLCO Cancer Screening Trial.
    Gohagan JK; Broski K; Gren LH; Fouad MN; Higgins D; Lappe K; Ogden S; Shambaugh V; Pinsky PF; O'Brien B; Yurgalevich S; Riley T; Wright P; Prorok PC
    Rev Recent Clin Trials; 2015; 10(3):187-93. PubMed ID: 26435288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort.
    Lacey JV; Kreimer AR; Buys SS; Marcus PM; Chang SC; Leitzmann MF; Hoover RN; Prorok PC; Berg CD; Hartge P;
    BMC Cancer; 2009 Mar; 9():84. PubMed ID: 19292893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive Quality Management (CQM) in the PLCO Trial.
    Gohagan JK; O'Brien B; Hasson MA; Umbel KD; Bridgeman B; Kramer BS; Reding D; Gren L; Wright P; Riley T; Prorok PC
    Rev Recent Clin Trials; 2015; 10(3):223-32. PubMed ID: 26238118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coordination and management of a large multicenter screening trial: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
    O'Brien B; Nichaman L; Browne JE; Levin DL; Prorok PC; Gohagan JK;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):310S-328S. PubMed ID: 11189685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The PLCO Cancer Screening Trial: Background, Goals, Organization, Operations, Results.
    Gohagan JK; Prorok PC; Greenwald P; Kramer BS
    Rev Recent Clin Trials; 2015; 10(3):173-80. PubMed ID: 26238115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Andriole GL
    Recent Results Cancer Res; 2014; 202():53-7. PubMed ID: 24531777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The PLCO Biorepository: Creating, Maintaining, and Administering a Unique Biospecimen Resource.
    Carrick DM; Black A; Gohagan JK; Khan A; Pettit K; Williams C; Yu K; Yurgalevitch S; Huang WY; Zhu C
    Rev Recent Clin Trials; 2015; 10(3):212-22. PubMed ID: 26238117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Pinsky PF; Miller A; Kramer BS; Church T; Reding D; Prorok P; Gelmann E; Schoen RE; Buys S; Hayes RB; Berg CD
    Am J Epidemiol; 2007 Apr; 165(8):874-81. PubMed ID: 17244633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Barry SA; Tammemagi MC; Penek S; Kassan EC; Dorfman CS; Riley TL; Commin J; Taylor KL
    J Natl Cancer Inst; 2012 Nov; 104(21):1647-59. PubMed ID: 23104210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of Self-Report of Chest X-Ray Exam at a Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Center.
    Gren LH; Lamerato LE; Wright P; Marcus PM
    Rev Recent Clin Trials; 2015; 10(3):194-9. PubMed ID: 26238206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model.
    Han SS; Erdogan SA; Toumazis I; Leung A; Plevritis SK
    Cancer Causes Control; 2017 Sep; 28(9):947-958. PubMed ID: 28702814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.
    de Koning HJ; Gulati R; Moss SM; Hugosson J; Pinsky PF; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; de Carvalho TM; Feuer EJ; Tsodikov A; Mariotto AB; Heijnsdijk EAM; Etzioni R
    Cancer; 2018 Mar; 124(6):1197-1206. PubMed ID: 29211316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial.
    Pinsky PF; Miller E; Prorok P; Grubb R; Crawford ED; Andriole G
    BJU Int; 2019 May; 123(5):854-860. PubMed ID: 30288918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.